

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>KOZLOV HERSH</u> (Last) (First) (Middle) <u>C/O VTV THERAPEUTICS INC.</u> <u>3980 PREMIER DRIVE, SUITE 310</u> (Street) <u>HIGH POINT NC 27265</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>vTv Therapeutics Inc. [VTVT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>07/01/2022</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Director stock option (right to buy)	\$0.72	07/01/2022		A		105,128		(1)	07/01/2032	Class A Common Stock	105,128	\$0	105,128	D	
Director stock option (right to buy)	\$2.65							(3)	06/11/2030	Class A Common Stock	26,250		26,250 ⁽²⁾	D	
Director stock option (right to buy)	\$2.54							(4)	05/03/2031	Class A Common Stock	15,000		15,000 ⁽²⁾	D	

Explanation of Responses:

- An option to purchase 80,128 shares vested immediately on July 1, 2022. The remaining option to purchase 25,000 shares vests on June 1, 2023.
- On June 15, 2020 and May 5, 2021, the reporting person filed Form 4s which inadvertently aggregated options to purchase shares of Class A common stock with different exercise prices and expiration dates. These errors have been corrected in the options beneficially owned in this Form 4.
- An option to purchase 2,812 shares vested immediately on June 11, 2020. The remaining option to purchase 23,438 shares vests in equal monthly installments over the three-year period beginning on June 11, 2020.
- Vests in equal monthly installments over the three-year period beginning May 3, 2021.

/s/ Richard S. Nelson as 07/06/2022
Attorney-in-Fact
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.